Portfolio managers
Phoeniks aggregates per-asset modelled yield into a portfolio view: production trajectory, physical-risk concentration by region and crop, and the disclosure inputs a manager needs for SFDR, PCAF or TNFD reporting — each traceable back to the individual asset.
- 7 / 29
- 21
- 9
- Per-parcel estimate, confidence band, audit trail
Portfolio view#
- Production trajectory aggregated from per-asset modelled yield.
- Physical-risk concentration by region, crop and water dependency.
- Disclosure inputs traceable from portfolio total down to a single holding.
- Scenario replay across the book rather than on a representative asset.
Frequently asked
- Does Phoeniks value farmland assets?
- No. It models physical production and its uncertainty. Valuation stays with the manager's own methodology and its appraisers.
Related pages
Banks and lenders
Per-parcel yield evidence for agricultural credit files: collateral defensibility, portfolio concentration and model-risk documentation lenders can file.
Reinsurers and insurers
Tail behaviour, spatial covariance and calibration evidence for crop and parametric portfolios, delivered as an actuarial validation pack.
Family offices and allocators
Compare farmland opportunities across countries on a single scoring basis, with sustainability disclosure inputs allocators can actually file.
Brokers and land agencies
Substantiate a farmland listing with modelled yield potential, environmental overlays and an exportable diligence pack buyers can review.
Farmland buyers
Assess a farmland parcel before the site visit: modelled yield, crop fit, environmental constraints and a shared pre-diligence room.
Auditors and verification bodies
Reproducible model runs, source provenance and evidence levels for external auditors and verification bodies reviewing agricultural claims.
Development finance institutions
Regional production and climate-exposure evidence for development banks and blended-finance programmes in data-sparse markets.
See also
Request access
Institutional access. No self-serve trial.